DIGIPATH (DIGP)

What we have here is a potential turnaround story. This is not our first involvement with DIGIPATH. We were hired in late 2018 to help communiate the story. We were successful ! Take a look at the chart in early 2019. Well... Hello Again !

Highlights:

  • The Company made continued progress on the development of our SabIR device, which is our fully-integrated NIR spectrometer that will enable instant field testing for THC, CBD and CBG markers in the field
  • Purchased a new Triple Quad 6500+ at the end of the quarter, which we expect will generate significant productivity improvements and cost savings once placed in service during the second fiscal quarter of 2020
  • First quarter revenues increased by $166,815, or 26%, on a year-over-year basis
  • Gross margins increased to 50%, from 25% in the prior year’s first fiscal quarter, as the Company improved processes to become more efficient
  • Adjusted EBITDA improved by $205,200 on a year over year basis, as the first quarter of 2020 was ($46,994), compared to Adjusted EBITDA of ($252,194) for the comparative fiscal quarter ending December 31, 2018
  • Net loss decreased to $220,427, compared to $462,174 for the comparative quarter ending December 31, 2018, an improvement of $241,747, or 52%

The full quarterly filing can be found on our website: Digipath SEC Filings

 

Client Updates Delivered
Straight To Your Inbox

Email: 
   
Confirm Email